{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:48:38Z","timestamp":1790621318037,"version":"4.1.0"},"reference-count":10,"publisher":"The Endocrine Society","issue":"2","license":[{"start":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:00:00Z","timestamp":1682035200000},"content-version":"vor","delay-in-days":63,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Type 1 diabetes mellitus (T1DM) with obesity is increasingly common, prompting effective clinical interventions to induce weight loss in this population. We present 3 patients with T1DM and obesity prescribed a glucagon-like peptide 1 receptor agonist (GLP-1RA) and pramlintide. Case 1: A 32-year-old male with obstructive sleep apnea (OSA) who lost \u221220.9\u2005kg (\u221216.1% of total body weight [TBW]) over 10 months on semaglutide and pramlintide. Case 2: A 68-year-old female with diabetic retinopathy, coronary artery disease, hypertension, hypothyroidism, and depression\/anxiety initially treated with topiramate, losing \u22128.4\u2005kg, but experiencing weight plateau. After adding dulaglutide and pramlintide, she lost an additional \u221212.8\u2005kg (\u221214.0% TBW) over 7 months, with total weight loss of \u221221.2\u2005kg (\u221223.1% TBW). Case 3: A 49-year-old female with hypertension, hypothyroidism, and depression who lost \u221214.6\u2005kg (\u221217.9% TBW) over 6 months on semaglutide and pramlintide. No significant side effects were experienced. All patients reported decreased insulin requirements on pramlintide, and hemoglobin A1c levels remained constant or decreased throughout the treatment period. Pramlintide and GLP-1RA resulted in excellent weight loss in our patients with obesity and T1DM. This combination may have a synergistic effect on the gut-brain axis. More research is required to substantiate these findings.<\/jats:p>","DOI":"10.1210\/jcemcr\/luad040","type":"journal-article","created":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T12:48:38Z","timestamp":1682081318000},"source":"Crossref","is-referenced-by-count":9,"title":["Combined GLP-1 Receptor Agonist and Amylin Analogue Pharmacotherapy to Treat Obesity Comorbid With Type 1 Diabetes"],"prefix":"10.1210","volume":"1","author":[{"given":"Gunther","family":"Wong","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Diabetes, Endocrinology & Metabolism, Vanderbilt University School of Medicine , Nashville, TN 37232 , USA"},{"name":"Vanderbilt Weight Loss Center, Vanderbilt University Medical Center , Nashville, TN 37204 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica M","family":"Garner","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Diabetes, Endocrinology & Metabolism, Vanderbilt University School of Medicine , Nashville, TN 37232 , USA"},{"name":"Vanderbilt Weight Loss Center, Vanderbilt University Medical Center , Nashville, TN 37204 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8326-3089","authenticated-orcid":false,"given":"Gitanjali","family":"Srivastava","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Diabetes, Endocrinology & Metabolism, Vanderbilt University School of Medicine , Nashville, TN 37232 , USA"},{"name":"Vanderbilt Weight Loss Center, Vanderbilt University Medical Center , Nashville, TN 37204 , USA"},{"name":"Department of Pediatrics, Vanderbilt University School of Medicine , Nashville, TN 37232 , USA"},{"name":"Department of Surgery, Vanderbilt University School of Medicine , Nashville, TN 37232 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2023,4,21]]},"reference":[{"issue":"5","key":"2024010813074862200_luad040-B1","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1210\/er.2017-00191","article-title":"Obesity in type 1 diabetes: pathophysiology, clinical impact, and mechanisms","volume":"39","author":"Corbin","year":"2018","journal-title":"Endocr Rev"},{"issue":"11","key":"2024010813074862200_luad040-B2","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41574-020-00411-y","article-title":"Nearly a decade on - trends, risk factors and policy implications in global obesity","volume":"16","author":"Malik","year":"2020","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"2024010813074862200_luad040-B3","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1464-5491.2010.02956.x","article-title":"Temporal patterns in overweight and obesity in type 1 diabetes","volume":"27","author":"Conway","year":"2010","journal-title":"Diabet Med"},{"issue":"Suppl","key":"2024010813074862200_luad040-B4","doi-asserted-by":"crossref","first-page":"47S","DOI":"10.1177\/0145721715607642","article-title":"Role of amylin in type 1 and type 2 diabetes","volume":"41-1","author":"Hieronymus","year":"2015","journal-title":"Diabetes Educ"},{"issue":"6","key":"2024010813074862200_luad040-B5","doi-asserted-by":"crossref","first-page":"R1475","DOI":"10.1152\/ajpregu.00703.2009","article-title":"The role of amylin in the control of energy homeostasis","volume":"298","author":"Lutz","year":"2010","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"8","key":"2024010813074862200_luad040-B6","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1177\/1060028016651279","article-title":"GLP-1 agonists in type 1 diabetes mellitus","volume":"50","author":"Janzen","year":"2016","journal-title":"Ann Pharmacother"},{"issue":"3","key":"2024010813074862200_luad040-B7","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3810\/pgm.2013.05.2635","article-title":"Pramlintide improved measures of glycemic control and body weight in patients with type 1 diabetes mellitus undergoing continuous subcutaneous insulin infusion therapy","volume":"125","author":"Herrmann","year":"2013","journal-title":"Postgrad Med"},{"issue":"1","key":"2024010813074862200_luad040-B8","doi-asserted-by":"crossref","first-page":"8447","DOI":"10.1038\/s41598-019-44591-8","article-title":"Combined amylin\/GLP-1 pharmacotherapy to promote and sustain long-lasting weight loss","volume":"9","author":"Liberini","year":"2019","journal-title":"Sci Rep"},{"issue":"10","key":"2024010813074862200_luad040-B9","doi-asserted-by":"crossref","first-page":"R885","DOI":"10.1152\/ajpregu.00520.2015","article-title":"GLP-1 and weight loss: unraveling the diverse neural circuitry","volume":"310","author":"Kanoski","year":"2016","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"2024010813074862200_luad040-B10","first-page":"203","article-title":"Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes","volume":"2","author":"Ryan","year":"2009","journal-title":"Drug Des Devel Ther"}],"container-title":["JCEM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/1\/2\/luad040\/51825381\/luad040.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/1\/2\/luad040\/51825381\/luad040.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T13:35:43Z","timestamp":1704720943000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcemcr\/article\/doi\/10.1210\/jcemcr\/luad040\/7135533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,17]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2,17]]}},"URL":"https:\/\/doi.org\/10.1210\/jcemcr\/luad040","relation":{},"ISSN":["2755-1520"],"issn-type":[{"value":"2755-1520","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,3,1]]},"published":{"date-parts":[[2023,2,17]]},"article-number":"luad040"}}